The Lillehei-Kaster aortic valve prosthesis. Long-term results in 273 patients with 1253 patient-years of follow-up.
The Lillehei-Kaster aortic valve prosthesis was inserted in 313 patients between August 1975 and December 1984. Aortic valve replacement alone was done in 193 patients. Additional procedures included coronary artery bypass grafting in 62 patients, mitral valve replacement in 22, mitral valvuloplasty in 8, and miscellaneous procedures in 28. The 273 patients discharged from the hospital are the basis of this report. They have been followed up for 1253 patient-years. The range of follow-up is 1 to 11 years, and the mean is 4.6 years. The 5-year survival rate for all patients was 68%, whereas for aortic valve replacement alone it was 76%. The incidences of embolism, thrombosis, bleeding, periprosthetic leak, valve infection, and reoperation per 100 patient-years were 1.5, 0.2, 2.0, 0.8, 0.7, and 1.3, respectively. The 5-year rates of freedom from embolism, thrombosis, bleeding, periprosthetic leak, valve infection, reoperation, and any valve-related complication were 94%, 99%, 91%, 96%, 97%, 94%, and 76%, respectively. Four of 16 patients who required reoperation had a properly functioning valve whose effective orifice area was too small for the cardiac output. Each of these valves was of the smaller size. There were no instances of mechanical valve failure. The Lillehei-Kaster aortic valve prosthesis is an excellent aortic valve substitute in the larger sizes. It has an extraordinary record for mechanical durability and an excellent resistance to thromboembolism in patients receiving proper anticoagulation. The incidence of perivalvular leak and infection is similar to that of other prosthetic valves. However, it is not to be recommended in the smaller sizes because of an unfavorable ratio of effective orifice area to tissue diameter.